FLT3 and acute myeloid leukemia: The multi-center Children’s Oncology Group AAML1031 trial investigated the feasibility and efficacy of incorporating sorafenib (a multi-kinase tyrosine kinase inhibitor (TKI)) when combined with standard AML chemotherapy in children and AYAs (age < 30 years) with de novo AML and FLT3-ITD with a high allelic ratio (>0.4) [118].